Bimeda Inc. announced the launch of Detomidine Hydrochloride, a sedative and analgesic used to facilitate minor surgical and diagnostic procedures in mature horses and yearlings, to veterinarians. This Detomidine Hydrochloride (ANADA 200 – 674) is the first and only U.S. Food and Drug Administration (FDA) approved bioequivalent to Dormosedan® sterile solution injection.
“This Detomidine Hydrochloride is a great addition to Bimeda’s equine product line. We have taken pride in providing superior animal health offerings to the industry for many years and are excited to bring the first FDA approved generic alternative to Dormosedan to the US market,” Gavin Tierney, Bimeda CEO, commented.
Bimeda currently offers Detomidine Hydrochloride Injection 10mg/mL in both 20mL and 5mL sizes.
Detomidine Hydrochloride meets the same quality and safety requirements as the pioneer (Dormosedan). Both products are equivalent in active and inactive ingredients (including carriers and excipients) in strength, dosage, form and route of administration. It is manufactured at an approved FDA facility and has the same label claims.
This announcement is an exciting advancement for both vets and equine owners alike and Bimeda is honored to continue being at the forefront of developing revolutionary products for the industry.
Bimeda is a leading global manufacturer, marketer and distributor of animal health products and veterinary pharmaceuticals. Bimeda US headquarters are based in Oakbrook Terrace, Illinois. Bimeda is focused on providing a comprehensive, customer-driven service and selling consistently high-quality products at a market-conscious price level.